Member Info for solow

I must be missing something. Maybe someone can point me to the profit warning? The Cash from operations is over 800 million. More than half the market cap. This number ignores all the accounting adjusting made to Profit. I am scratching my head on this.

And it is that attitude that will keep the share price suppressed.

The upcoming exploration projects wont cost more than a few million each. Abra cost 1.6 million. What is happening to the rest of the 170 million odd, I think is a fair question from a shareholder. I have a small percent in here that I bought way back. I would, however, like to be tempted to buy more.

I really find it so strange that shareholders here aren´t bothered that they aren´t even being given the option of a special dividend. And yet they wonder why the share price is so low. Incredible.

I think the issue with the share price is that most investors want clarity first. I invest first and foremost in a company that is well run and has cimmunicated a clear strategy. Metals Exploration seems to be well run but is not communicating what is happening to all the money. And last i checked that is why we are all here. The CEO, however good he is, works for the shareholders and he needs to be held to account. The opposite seems to be heppening. We have known for almost a year that a lot of money is coming down the track and he hasnt accounted for any of it. That needs to change.

I want to see from the BOD some idea of how the future cashflow will be apent or returned to shareholders. There is an awful lot of money coming down the teack over the next few years and there should be some information given to shareholders of how this will be spent. What is the budget for exploration and commercialisation? Is there even a thought of a special divi? This needs to be cleared up for me to invest more.

Digitt, consider that in 2023, according to Fiercepharma, $23 billion of private funding flowed into Biotech companies, many of which are pre-clinical. This is of course down from the heady days of Covid. But this is still a decent amount. The top private deals were in the 100s of millions. So I only wonder why Hemo's begging bowl only atrracted such a small amount. And also zero attention from big Pharma.

Hemo market cap is well down historically. Consider even that one could justifiably knock another 30% off todays market cap when comparing with 2019 (to account for inflation) and then the company looks very cheap. What puts me off buying more, however, is that the company needs around 6 mill a year to keep going, and so every year or so gives away a massive chunk of shares in order to lurch fwd another year. And why was this last equity raise so low? There is loads of private equity money looking for biotech investment. Why did Hemo have to raise at 2p per share? To me the answer is that the money out there has found better alternatives to Hemo. Either because there are indeed better alternatives or because Vlad and Co havent been selling Hemo very well as a company. Neither option will change soon which doesnt bode well for future fund raising and dilution. Which worries me and puts me off buying more.

Is it a coincidence that Vlads salary has jumped by over 35% from 280k in 2022 to a sniff under 400k in 2023, and that the share price has fallen by around 35% during that time?

The fact is that DB has clearly stated that the cash from current operations is being spent on exploration and development. I wouldnt expect any divis any time soon. On top of which DB has sold his own mining rights to MTL. Consider that MTL disclosed that in 2022 it was pursueing other mining opportunities in the Philippines. Yet it now has bought rights to Abra from its own CEO. Doesnt smell right.

A question. The last update from MTL gave Depleted Ore Reserves of 0.22 MOz as of Dec 2023. MTL produces around 80,000 oz of gold per year. With 220,000 oz from Dec 2023 remaining, am i correct then in thinking that MTL has just over 2 year of production from today?

Why no dividends? This was the moment i was waiting for. I have cut half my holdings now. With sadness as I have been invested here for years and before current management. Who have done a remarkable job. However, without shareholder returns now, to me this becomes a minimum 5 year investment before possible returns and good luck forecasting gold prices over that period.

It was a buy from me

JHFH, you do put out a large volume of what is essentially hot air. Hemogenyx didn´t know better than us when it raised the convertible debt a few years ago. I sold out at around 7p and bought back in around 2p.

Dhub, I wouldn´t read too much into Prevail paying over the odds for the shares. The share price paid is part of the larger scope that actually involves Hemo paying out to a Prevail affiliate over the life of the P1 clinical trials. So I see the share price paid as not very relevant to Prevail´s view of the company. I dont know much about how these types of relationships are structured but it definately more complicated than a simple share purchase.

This sentence from the RNS says alot: The subscription funds will in large part defray the payment made by the Company for the first stage of the work being undertaken by InfoWorks under the MSTA.

The only issue I can find is this:

Tax & Royalty

• The Company has an income tax holiday until July 2022. From July

2022 mining license terms entitles Philippine government to a

minimum 50% of net cash revenue via income tax, VAT, import

duties, excise tax, and other business rates/taxes. Excise tax rates

are 4%.

So I take it that once that debt is repaid, shareholders will have to share profits with the tax man. This is from the Feb 2022 investor presentation. If true, the company would be incentivised to invest money rather than paying out to shareholders. Thoughts anyone?

Yes i am a long term investor but i dont follow this company very closely. I dont pretend to understand the risk/reward nature of this company. I did ask the question in good faith and i am surprised that Vlad would claim something is far off the truth. I think generally that he is very honest and competent and that this company is a good long term hold. But why he claims that Hemo is saving lives now is beyond me.

Not at all. Genuine request for info.

Super news. I didnt think the CBR was yet saving lives. Is this true? Can someone please confirm exactly which product from Hemos pipeline is saving lives?

Anyone know what came of the practice at Harley Street that years back was ear marked to treat the first patient . A SPAC will probably want to understand all the history behind AVO going back years. Will mean taking up quite a few carpets no doubt. I would imagine that AVO have put the feelers out already to the big boys in proton therapy. No takers. No one is interested. Makes me wonder.

I own Echo. Not much and not really worth the effort to sell at such a loss. 90% down or something like that. This is a company that last posted an operating loss of almost a third of revenue. It was only FX tailwinds that pulled the net loss back. All this at a time of high oil and gas prices. Even if the company did make a profit, that money would go into most exploration and risk. So shareholders wouldnt see any returns for a decade. I don´t see how anyone would want to invest here. Happy to be convinced otherwise.

The Jan 18 RNS gives the clearest picture yet of AVO´s approach to manufacturing the LIGHT system. The intend to 3d print some of the components and the rest of the components come from 850 different suppliers. Did I read that correctly? They are ordering the parts off Alibaba and then have a few chaps in Danesbury with a mechano set putting the machines together. This is their manufacturing process? Incredible. I remember the talk years ago of Thales being the manufacturer. What a let down. Plus a massive dilution coming down the track, no wonder the sp is going south.